Title: Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses

Authors names and affiliations:

David A. Muller1,2, Frances E. Pearson1, Germain J.P. Fernando1,2, Christiana Agyei-Yeboah1, Nick S. Owens1, Simon R. Corrie1,2, Michael L. Crichton1, Jonathon C.J. Wei1, William C. Weldon3, M. Steven Oberste3, Paul R. Young2,4, Mark A. F. Kendall1,2*.

1Delivery of Drugs and Genes Group (D2G2), Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia.

2Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia.

3Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

4School of Chemical and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia.

*Corresponding author: Professor Mark Kendall

Address: The University of Queensland, Delivery of Drugs and Genes Group, Australian Institute for Bioengineering and Nanotechnology, Building 75, St Lucia, Queensland, 4072. Australia

Tel: +61 7 334 64203  Fax: +61 7 334 64197

Email: m.kendall@uq.edu.au
Supplementary data:

Figure S1: Neutralising antibody titres prior to immunisation. Seropositivity was defined as a titre \( \geq 3.0 \log_2 \) (the dotted line).